PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Korea's Hospital Polypharmacy Program Cuts 90-Day Readmissions in Elders

polypharmacymedication reconciliationdeprescribingolder adultsgeriatric pharmacyreadmissioncost-benefit analysisBeers Criteriaretrospective cohorthealth economicsKorea NHIS Geriatrics

Background Information

Polypharmacy management slashes readmission rates and costs for older adults.

Polypharmacy is linked to negative outcomes in older adults, and managing it can reduce readmission rates and healthcare costs. The polypharmacy management program lowered 90-day readmission risk (adjusted hazard ratio 0.85) and reduced hospitalization costs (USD$6400 vs USD$6740, P = 0.005). Despite the lack of randomization, propensity score matching strengthens the findings, suggesting potential for broader implementation in healthcare systems. Korea's polypharmacy management program significantly reduced readmissions and healthcare costs for older adults.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Jang S, Lim J, Moon A, Lee JY, Ah YM, Lee HJ, Lee SY, Kim JH, Jang S

Citation: Jang S, Lim J, Moon A, et al. Clinical and Economic Outcomes of Korea's National Polypharmacy Management Program for Hospitalized Older Adults: 90-Day Readmission and Healthcare Costs. Drugs & aging. 2026;43(9):849-860. doi:10.1007/s40266-026-01325-6

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.